Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02127307 · ClinicalTrials.gov registry record
Phase 4 Study to Demonstrate Prognostic Usefulness of AdreView™ Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience Death During 60 Months Follow-up.
A clinical trial, sponsored by GE Healthcare.
- Completed
- Registry status
- 964
- Enrollment target
NCT02127307 is a clinical trial that has completed, run by GE Healthcare. The registered enrollment target is 964 participants.
The verdict
NCT02127307 has completed, sponsored by GE Healthcare.
- COMPLETED
- Registry status
- 964 participants
- Enrollment target
Study Summary
This aim of the study is to investigate the prognostic usefulness of AdreView™ imaging to identify those subjects with New York Heart Association (NYHA) Class II or III HF who will die during 60 months of follow-up from the date of administration of AdreView™ in prior studies MBG311, MBG312, or MBG312C (hereafter included in MBG312).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 964 participants |
| Start Date | 2014-02 |
| Est. Completion | 2016-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02127307
The ClinicalTrials.gov registry entry for NCT02127307 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 964 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GE Healthcare, which has 99 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02127307 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02127307 about?
NCT02127307 is a clinical study titled "Phase 4 Study to Demonstrate Prognostic Usefulness of AdreView™ Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience Death During 60 Months Follow-up.". This aim of the study is to investigate the prognostic usefulness of AdreView™ imaging to identify those subjects with New York Heart Association (NYHA) Class II or III HF who will die during 60 months of follow-up from the date of administration of AdreView™ in prior studies MBG311, MBG312, or MBG3...
What is the current status of trial NCT02127307?
This trial is currently completed. The enrollment target is 964 participants. The study started on 2014-02. Estimated completion is 2016-04.
Who is sponsoring clinical trial NCT02127307?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.